Ophthalmology

FDA discards depression drug ALKS 5461 of Alkermes The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combination of buprenorphine and samidorphan. Alkermes designed the combination to act on the mu- and kappa-opioid receptors that eventually showed improved results in people, who showed unresponsiveness to present antidepressant therapies.  Alkermes said that the FDA wanted more clinical data to give significant evidence for the effectiveness of ALKS 5461. An atlas of HIV shows escape routes that could improve vaccine design The scientists at the Fred Hutchinson Cancer Research Center made an atla...